Study of lonitoclax for returning B-cell blood cancers
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new drug, lonitoclax, in people with certain B-cell blood cancers that have come back or not responded to earlier treatments. It aims to see if the drug can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of B-cell cancer, like CLL, SLL, or certain lymphomas, that has returned or not responded to treatment.
- You have tried at least 1 or 2 prior therapies, depending on your specific cancer type.
- Your blood cell counts and organ function meet minimum levels (checked through blood tests).
- You are able to perform daily activities with some help (ECOG score 0-2).
- If you could become pregnant or father a child, you agree to use effective birth control during and for 90 days after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (zanubrutinib and sonrotoclax) as a first treatment for people with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). It aims to see if this approach works better than standard care by using a test called MRD to guide treatment duration.
This study tests a two-step approach for people who have just been diagnosed with CLL or SLL and need treatment. It starts with a medicine called zanubrutinib, then adds another drug called sonrotoclax for a set period of time. The goal is to see if this combination can control the disease for a long time and maybe allow people to stop treatment after a while.
This trial tests whether a combination of two newer drugs can help people with certain types of B-cell lymphoma that have come back or not responded to treatment. The drugs target cancer cells differently than older treatments, possibly offering a new option.
This trial tests a new drug called Lonitoclax combined with azacitidine for people with AML that has come back or not responded to prior treatment. The study will see if the combination is safe and can help control the leukemia.
This trial tests a three-drug combination for people who have not yet had treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It aims to improve outcomes with a targeted, mostly oral regimen.
This trial tests whether adding a new drug, sonrotoclax, to the standard treatment zanubrutinib works better for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who haven't had treatment before. It's for patients aged 65 and older who need therapy due to symptoms or blood cell issues.
Hear when a new CLL/SLL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.